{"href":"https://api.simplecast.com/oembed?url=https%3A%2F%2Foncologypodcast.simplecast.com%2Fepisodes%2Fdosing-in-later-line-crc-tx-xpfGlqAl","width":444,"version":"1.0","type":"rich","title":"Optimal Dosing Strategies With Regorafenib and TAS-102 for Patients With Metastatic Colorectal Cancer","thumbnail_width":300,"thumbnail_url":"https://image.simplecastcdn.com/images/86952976-b928-4317-884c-2c7ba3b2ae4d/21a22a8c-b6e8-44a9-8734-426d5c3e822f/vegf-tki-am-podcasticon-later-line.jpg","thumbnail_height":300,"provider_url":"https://simplecast.com","provider_name":"Simplecast","html":"<iframe src=\"https://player.simplecast.com/da3bcbc5-73db-464e-9816-f5b2a811b472\" height=\"200\" width=\"100%\" title=\"Optimal Dosing Strategies With Regorafenib and TAS-102 for Patients With Metastatic Colorectal Cancer\" frameborder=\"0\" scrolling=\"no\"></iframe>","height":200,"description":"Listen to Kanwal Raghav, MD, and Rachel Riechelmann, MD, PhD, as they provide their clinical insights into dosing of key later-line treatment options for patients with mCRC."}